• Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c 
  • More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse
  • IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function
  • Pivotal results will be presented at EHA 2026